72例肺腺鳞癌临床病理特点和预后因素分析  

Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma

作　　者：吴熙[1] 李峻岭[2] 陈舒兰[3] 于雷[1] 杨渤彦[1] 

机构地区：[1]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院综合科,北京100021 [2]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院内科,北京100021 [3]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院病案室,北京100021

出　　处：《中国肺癌杂志》2016年第10期653-658,共6页Chinese Journal of Lung Cancer

摘　　要：背景与目的肺腺鳞癌是肺癌中的一种少见类型,混合有腺癌和鳞癌两种恶性组织成分,侵袭性高、预后差。本研究旨在探讨腺鳞癌的临床病理特点和预后影响因素。方法对72例肺腺鳞癌患者的临床病理资料进行回顾性分析,探讨影响患者预后的因素。结果全组患者中位生存期位34.7个月,5年生存率为14.9%,肿瘤长径、转移(metastasis,M)分期、肿瘤-淋巴结-转移(tumor-node-metastasis,TNM)病理分期、基因突变、手术对患者预后的影响有统计学意义。结论肺腺鳞癌恶性程度高、预后差,应采取手术为主的综合治疗,小分子酪氨酸激酶抑制剂治疗有助于延长患者生存期。Background and objective Adenosquamous carcinoma（ASC） is a rare subtype of lung cancer, it is mixed glandular and squamous cell carcinoma with a more aggressive behavior and poor prognosis than the other histologic subtypes. The aim of the study was to explore the clinicopathological characteristics and prognostic factors of ASC. Methods A total of 72 patients were enrolled. We investigated clinicalpathological features and prognostic factors retrospectively. Results The overall 72 ASC patients＇ median age was 34.7 months, 5-year survival rate was 14.9%. The influence of tumor size, M stage, and N stage, gene mutation and surgery on the prognosis of patients show statistical significance. Conclusion ASC is characterized by both histologic aggressiveness and adverse prognosis. We suggest the comprehensive therapy based on surgery, and given small molecule tyrosine kinase inhibitors（TKIs） treatment may prolong patients＇ overall survival.

关 键 词：肺肿瘤 腺鳞癌 临床病理 预后 

分 类 号：R734.2[医药卫生—肿瘤]